CA2427312A1 - Chimere de fragments de proteines genetiquement modifie et methodes d'utilisations - Google Patents

Chimere de fragments de proteines genetiquement modifie et methodes d'utilisations Download PDF

Info

Publication number
CA2427312A1
CA2427312A1 CA002427312A CA2427312A CA2427312A1 CA 2427312 A1 CA2427312 A1 CA 2427312A1 CA 002427312 A CA002427312 A CA 002427312A CA 2427312 A CA2427312 A CA 2427312A CA 2427312 A1 CA2427312 A1 CA 2427312A1
Authority
CA
Canada
Prior art keywords
seq
protein
group
sequence selected
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002427312A
Other languages
English (en)
Inventor
Kent D. Stewart
Kevin R. Steffy
Dale J. Kempf
Kevin S. Harris
Jeffrey R. Huth
Vincent S. Stoll
John E. Harlan
Iok C. Ng
Stephen F. Betz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2427312A1 publication Critical patent/CA2427312A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles protéines relatives à la protéine gp41 du virus de l'immunodéficience humaine de type 1 (HIV-1), ainsi que de nouvelles méthodes d'utilisation de celles-ci. On peut par exemple utiliser ces protéines dans le criblage de composés anti-HIV.
CA002427312A 2000-10-27 2001-10-26 Chimere de fragments de proteines genetiquement modifie et methodes d'utilisations Abandoned CA2427312A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69831100A 2000-10-27 2000-10-27
US09/698,311 2000-10-27
PCT/US2001/048040 WO2002034909A2 (fr) 2000-10-27 2001-10-26 Chimere de fragments de proteines synthetisee et ses methodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2427312A1 true CA2427312A1 (fr) 2002-05-02

Family

ID=24804726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002427312A Abandoned CA2427312A1 (fr) 2000-10-27 2001-10-26 Chimere de fragments de proteines genetiquement modifie et methodes d'utilisations

Country Status (5)

Country Link
EP (1) EP1379646A2 (fr)
JP (1) JP2004528011A (fr)
CA (1) CA2427312A1 (fr)
MX (1) MXPA03003696A (fr)
WO (1) WO2002034909A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390525C2 (ru) 2003-07-30 2010-05-27 Майметикс Корпорейшн Новая растворимая и стабилизированная тримерная форма полипептидов gp41
JP4551160B2 (ja) * 2003-10-24 2010-09-22 株式会社島津製作所 標識アミド化を用いたタンパク質又はペプチドの解析法
CN109406469B (zh) * 2018-10-24 2021-04-09 中国医科大学 基于蛋白结合诱导dna双链变构的检测色氨酸的方法
CN116759132A (zh) * 2023-04-17 2023-09-15 南京大学 Dna分子线及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040616A1 (fr) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1

Also Published As

Publication number Publication date
WO2002034909A3 (fr) 2003-11-13
WO2002034909A2 (fr) 2002-05-02
MXPA03003696A (es) 2005-01-25
EP1379646A2 (fr) 2004-01-14
JP2004528011A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
Baker et al. Structural basis for paramyxovirus-mediated membrane fusion
Momany et al. Crystal structure of dimeric HIV-1 capsid protein
JP4456671B2 (ja) Ｊｃ−ウイルスのｖｐ−抗原
JP4589420B2 (ja) Ｈｉｖ−１のｏグループ（またはサブグループ）レトロウイルス性抗原のヌクレオチド配列
Morellet et al. Helical structure determined by NMR of the HIV‐1 (345–392) Gag sequence, surrounding p2: Implications for particle assembly and RNA packaging
US20020077284A1 (en) Inhibitors of HIV membrane fusion
US9181300B2 (en) Polypeptides for treating and/or limiting influenza infection
Mortuza et al. Structure of B-MLV capsid amino-terminal domain reveals key features of viral tropism, gag assembly and core formation
NO870027L (no) Ekspresjon av htlv-iii gag-gen.
Joyce et al. Crystal structure and immunogenicity of the DS-Cav1-stabilized fusion glycoprotein from respiratory syncytial virus subtype B
AU770482B2 (en) Inhibitors of HIV membrane fusion
JP2011515074A (ja) インフルエンザ・ウイルスｐａの発現精製及びｐａのｎ末端及びｐａのｃ末端とｐｂ１のｎ末端ポリペプチド複合体の結晶構造
Oshima et al. Effects of blocking individual maturation cleavages in murine leukemia virus Gag
US20050221285A1 (en) Method for identifying or screening anti-viral agents
Matúz et al. Inhibition of XMRV and HIV‐1 proteases by pepstatin A and acetyl‐pepstatin
CA2427312A1 (fr) Chimere de fragments de proteines genetiquement modifie et methodes d'utilisations
JP3439208B2 (ja) Ｈｔｌｖ−▲ｉ▼及びｈｔｌｖ−▲ｉｉ▼ペプチド抗原及び方法
HUE035432T2 (en) The gp120 variant of HIV
JP2003523188A (ja) Ａｉｄｓ先祖ウイルスおよびワクチン
US20090087445A1 (en) Method for the Redox Potential-Dependent Detection of Target Molecules by Interacting Polypeptides
US20010043931A1 (en) Human respiratory syncytial virus
CN116472278A (zh) 与埃博拉病毒疫苗相关的组合物和方法
US20030064061A1 (en) Bcr-Abl oligomerization domain polypeptides and uses therefor
Brun et al. Electrostatic repulsion between HIV‐1 capsid proteins modulates hexamer plasticity and in vitro assembly
US7960504B2 (en) Inhibitors of HIV membrane fusion

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued